UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000014330
Receipt number R000016682
Scientific Title A Phase I Study of Pemetrexed, Carboplatin, and Radiation Therapy in Locally Advanced Non-Squamous-Cell, Non-Small-Cell Lung Cancer
Date of disclosure of the study information 2014/06/23
Last modified on 2017/07/10 15:39:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Phase I Study of Pemetrexed, Carboplatin, and Radiation Therapy
in Locally Advanced Non-Squamous-Cell, Non-Small-Cell Lung Cancer

Acronym

PRINCE

Scientific Title

A Phase I Study of Pemetrexed, Carboplatin, and Radiation Therapy
in Locally Advanced Non-Squamous-Cell, Non-Small-Cell Lung Cancer

Scientific Title:Acronym

PRINCE

Region

Japan


Condition

Condition

elderly patients with localy advanced non-small-cell lung cancer

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To determine the maximum-tolerated dose (MTD) and the recommended dose (RD) of radiation and CBDCA+Pemetrexed

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase I


Assessment

Primary outcomes

To determine the maximum-tolerated dose (MTD)

Key secondary outcomes

ORR, PFS, OS


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

CBCDA: AUC4-5, weekly
PEM:500mg/m2, weekly
concurrent TRT: 2Gy/day todal 60Gy

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

75 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Histologically or cytologically confirmed non-sqamous non-small-cell lung cancer with Chemo-naive patients
2) Stage III, without indication for curative resection, with irradiation
3) Patients aged 75- years
4) ECOG performance status 0-1
5) Adequate organ function
6) Excepted to live over 3 months after administration day
7) Written informed consent from the patients

Key exclusion criteria

1) squamous cell carcinoma
2) Interstitial pneumonia or pulmonary fibrosis detectable on Chest X-ray
3) Pleural effusion, pericardial effusion and ascites to need treatment
4) Severe renal function disorder
5) SVC syndrome
6) Brain metastases with neurological symptoms
7) Active double cancer
8) Uncontrollable diabetes mellitus and hypertenson
9) Liver cirrhosis by image findings or laboratory examinations
10) History of severe heart disease (myocardial infarction within 6 months, unstable angina, post-PTCA or CAGB, signs of congestive heart failue, arrythmia with past history of heart failure, etc.)
11) Pregnancy, breast feeding and suspected pregnancy
12) History of grave drug allergic reaction
13) Acute inflammatory disease
14) An agreement is not obtained for support therapy such as transfusion etc
15) Having the bleeding tendency which is clinically apparent
16) Patients whose participation in the trial is judged to be inappropriate by the attendeing doctor

Target sample size

12


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tomoya Kawaguchi

Organization

Osaka City University Hospital

Division name

Chemotherapy center

Zip code


Address

1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

TEL

06-6645-3793

Email

y-naruo@sc4.so-net.ne.jp


Public contact

Name of contact person

1st name
Middle name
Last name Naruo Yoshimura

Organization

Osaka City University Hospital

Division name

Chemotherapy center

Zip code


Address

1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

TEL

06-6645-3793

Homepage URL


Email

y-naruo@sc4.so-net.ne.jp


Sponsor or person

Institute

Osaka Lung Cancer Study Group

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 06 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2012 Year 01 Month 01 Day

Date of IRB


Anticipated trial start date

2013 Year 02 Month 01 Day

Last follow-up date

2017 Year 01 Month 31 Day

Date of closure to data entry

2017 Year 03 Month 01 Day

Date trial data considered complete

2017 Year 04 Month 01 Day

Date analysis concluded

2017 Year 05 Month 01 Day


Other

Other related information



Management information

Registered date

2014 Year 06 Month 20 Day

Last modified on

2017 Year 07 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016682


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name